Geriatric pharmacoeconomics: cost savings from deprescribing and appropriate prescribing

Canada is concerned about drug safety in seniors and unsustainable drug costs. Geriatric pharmacoeconomics reveals the hidden costs associated with drug harms, such as falls and hip fractures, in the case of benzodiazepine drugs.  We are studying the re-allocation of funds from the reimbursement of inappropriate drugs to alternate non-pharmacological therapies, and aim to develop economic solutions and budget impact analyses.

Co-investigators: Dr. Cara Tannenbaum, Dr. Vakaramoko Diaby, Dr. Mathieu Boulin, Dr. Steve Morgan, Dr. Justin Turner, Université de Montréal

Contact: camille.gagnon@criugm.qc.ca

Funder (2014-2016): Michel Saucier Chair in Pharmacology, Health and Aging at the Université de Montréal

Publications:

  • Tannenbaum C, Diaby V, Singh D, Perreault S, Luc M, Vasiliadis HM. Sedative-hypnotic medicines and falls in community-dwelling older adults: a cost-effectiveness (decision-tree) analysis from a US Medicare perspective. Drugs Aging. 2015 Apr; 32(4):305-14. http://www.ncbi.nlm.nih.gov/pubmed/25825121
  • Morgan S, Hunt J, Rioux J, Proulx J, Weymann D, Tannenbaum C. Frequency and cost of potentially inappropriate prescribing for older adults: a cross-sectional study. CMAJ Open. 2016 Jun 22;4(2):E346-51.
  • Boulin M, Diaby V, Tannenbaum C. Preventing Unnecessary Costs of Drug-Induced Hypoglycemia in Older Adults with Type 2 Diabetes in the United States and Canada. PLoS One. 2016 Sep 20;11(9):e0162951.